Skip to main content
Equibles
LCTX logo

LCTX · Lineage Cell Therapeutics, Inc. · Analyst Estimates

Track LCTX — free

Use LCTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LCTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.01 -0.01 (-0.98%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Customer concentration — top 2 customers 92% of revenue

2 customers — 92% of revenue (the year ended December 31, 2025)

“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”

One customer — 92% of revenue (the year ended December 31, 2024)

“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
View the 10-K filed Mar 5, 2026
Market Cap
$255.44M
Shares
252.91M

Analyst Estimates

Compare analyst forecasts for Lineage Cell Therapeutics, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Only independently verified consensus published through the company's investor-relations sources is available.

Consensus not yet available

Only independently verified consensus published through the company's investor-relations sources is available.

Key facts CIK 876343 CUSIP 53566P109 13F (30d) 34 filings 34 filers Visit website Investor relations